UBS analyst Daniel Brennan raised his price target on (DHR) to $144 from $125 following its deal to purchase the GE Biopharma (GE) division. He said the company tripled its exposure to the sector and materially improved its financial profile with the GE deal. The analyst added that he sees management assumptions on organic growth rate, EBITDA margins, and earnings accretion as conservative. Brennan reiterated his Buy rating on Danaher shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.